31 Oct TomoTherapy confirms 59 percent increase in Q3 revenue
Madison, Wis. – TomoTherapy has confirmed what it anticipated earlier this year – that its 2007 third quarter would see record-breaking sales.
TomoTherapy, which manufactures and sells the Hi·Art radiation therapy system for the treatment of a wide variety of cancers, had revenues of $59.2 million, a 59 percent increase over the $37.2 million reported for the third quarter of 2006.
Perhaps even more telling, the value of new sales orders received during the third quarter of 2007 totaled $73 million, an 82 percent increase over the third quarter of 2006. As of Sept. 30, 2007, TomoTherapy’s revenue backlog totaled $228 million, a 10 percent increase over the backlog that existed at the end of Q2 2007.
The company reported net income was $2.6 million, or $0.05 per diluted share, compared to pro forma net income of $3.1 million, or $0.08 per diluted share, for the third quarter of 2006.
For the first nine months of 2007, TomoTherapy reported revenue of $154.1 million, a 60 percent increase from the $96.5 million for the first three quarters of 2006.
• TomoTherapy forecasts 61 percent Q3 revenue surge
• TomoTherapy files to sell 8.5 million additional shares of stock
• TomoTherapy sells first radiation therapy system in China